fig1

Figure 1. Evolution of systemic treatments of aBTCs. aBTCs: Advanced biliary tract cancers; L: line; ICIs: immune checkpoint inhibitors; m: mutations; f: fusions; a: amplifications; italic: under current clinical investigation; CISGEM: cisplatin + gemcitabine; FOLFOX: 5-fluorouracil + folinic acid + oxaliplatin; Nal-IRI: nanoliposomal irinotecan; FOLFIRINOX: 5-fluorouracil + folinic acid + oxaliplatin + irinotecan; PARPi: poly-ADP ribose polymerase inhibitors.